SNDX SYNDAX PHARMACEUTICALS INC Company Mergers 8-K Filing 2024 - Royalty Sale Agreement Syndax Pharmaceuticals sold rights to receive a percentage of net sales from axatilimab products to Royalty Pharma for $350 million, with a royalty rate of 13.8% and a cap of $822.5 million on total payments.Get access to all SEC 8-K filings of the SYNDAX PHARMACEUTICALS INC